Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY RESULTS: Medical Marijuana

Decreased levels of vitamin D associated with reduced methylation in African American teens

Sweep Away Senile Cells

PAIN'S SECRET MESSAGE: Why Prince Didn't Need to Die

8 Hacks to Slash Medication Costs

Relief from Common Digestive Distress

New Study Shows Optimized Curcumin Stops Inflammation

7 Natural Ways to Prevent Diabetes

Block The Vascular Origins Of Cognitive Decline

Curcumin: Your Secret Weapon to Speed Muscle Recovery After Intense Exercise

 
Print Page
Email Article

Arthritis Breakthrough: Drug combo may produce remission in newly-developed RA & very early arthritic disease

  [ 11 votes ]   [ Discuss This Article ]
www.ProHealth.com • November 7, 2010


Nearly two-thirds of early or incipient RA patients achieved remission (Disease Activity Score under 1.6) with combination of methotrexate and prednisone. Now, is drug-free remission possible for them?

People with newly-developed rheumatoid arthritis or very early “undifferentiated arthritis” may be able to achieve remission, with continued drug therapy, after four months of treatment with methotrexate and prednisone, according to research to be presented at 3:30 pm Tuesday, Nov 9 at the American College of Rheumatology Annual Scientific Meeting in Atlanta.[1]

Rheumatoid arthritis is a chronic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints are the principal body parts affected by RA, inflammation can develop in other organs as well.

An estimated 1.3 million Americans have RA, and the disease typically affects women twice as often as men. The new ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria are based on the recognition that undifferentiated arthritis may be the earliest clinical manifestation of RA.

Researchers recently assessed whether people with RA (which had developed less than two years before the start of the study) or undifferentiated arthritis (defined, for this study, as having arthritis in more than one joint and being considered at risk for developing RA) could achieve remission after four months of taking a combination of methotrexate and prednisone.

Throughout the course of the study, researchers followed 261 people with RA and 161 people with undifferentiated arthritis who were taking 25 mg per week of methotrexate and 60 mg per day of prednisone, which was tapered down to 7.5 mg per day over the course of seven weeks.

According to C F (Renée) Allaart, MD, PhD - associate professor of rheumatology at Leiden University Medical Center in Leiden, The Netherlands, and an investigator in the study - this is first study to treat early RA and undifferentiated arthritis patients with progressive combination therapy, which was previously reserved for active, more advanced RA.

The goal was to see if participants could achieve remission based on a Disease Activity Score under 1.6. Researchers measured this clinical outcome and considered functional abilities when making their final assessments of the success of the combination of methotrexate and prednisone.

They found that remission was achieved in:

• 153 (58.6%) of the participants with RA

• And 107 (66.5%) of the participants with undifferentiated arthritis.

• Altogether, the disease went into remission in 63% of patients.

There was improvement in the average DAS scores of participants of 1.90 for participants with RA, and 1.32 in participants with undifferentiated arthritis. There was also an improvement in overall functionality reported by participants in both groups.

Participants in both groups who began the study with lower DAS scores were more likely to achieve remission after four months of the combined treatment.

“The results show that - in this group of patients with earlier, and on average less active RA - remission percentages are higher than with similar treatment in more active RA, and that the addition of high-tapered-to-low prednisone to methotrexate works in undifferentiated arthritis,” says Dr. Allaart.

She notes that previously published early remission rates for active RA are less than 30% (depending on initial treatment).

“We now will try to taper and stop the medication in order to achieve drug-free remission,” she adds.

This ongoing study will continue to report on the patients who achieved remission and had their medications discontinued.

More than 600 patients have now been included, and the study will begin a second phase where participants with RA and undifferentiated arthritis who have not achieved remission while taking methotrexate with prednisone are randomly placed in two treatment groups.

• One group will be given multiple disease-modifying antirheumatic drugs (such as methotrexate, sulfasalazine, hydroxychloroquine, and low-dose prednisone),

• While the other group will be given an anti-TNF (adalimumab) with methotrexate.

The aim remains to achieve (ultimately drug-free) remission.

“The results of the randomized, second phase of the study will determine whether there is still a place for conventional DMARD therapy after failure on methotrexate and prednisone, or whether anti-TNF is the best option for early remission induction treatment,” Dr. Allaart says.

For now, she suggests the optimal strategy is to start treatment early and aim at remission.

“A short initial course of prednisone, even at a relatively high dose, is probably preferred over delayed but long-term low prednisone dosages in patients with RA,” she says.

“We found that even with relatively mild or little joint involvement, patients are motivated to take progressive medication in order to achieve early remission.”

Patients should talk to their rheumatologists to determine their best course of treatment.

___
1. Presentation # 1396, “Induction Therapy with Methotrexate and Prednisone in Rheumatoid or Very Early Arthritic Disease: IMPROVED Study,” by KVC de Boer, et al. Leiden University. For more information about the meeting, visit www.rheumatology.org/education. Follow the meeting on twitter (http://twitter.com/acrheum) by using the official hashtag: #ACR2010.

Source: American College of Rheumatology press release, Nov 7, 2020




Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Ultra EPA  - Fish Oil Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
20 Helpful Tips for Cleaning and Organizing When You're Chronically Ill

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Looking for Energy? Turn to Plants. Looking for Energy? Turn to Plants.
The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol
Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season
The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health
Priming Your Immune System for Cold & Flu Season Priming Your Immune System for Cold & Flu Season

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler

· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map